Detailed description page of ThPDB2

This page displays user query in tabular form.

10858 details
Primary information
ID10858
Therapeutic IDTh1220
Protein NameBrodalumab
SequenceNA
Molecular Weight1,44,000
Chemical FormulaC6372H9840N1712O1988S52
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionBrodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Indication/DiseaseBrodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
PharmacodynamicsIncrease in the level of IL-17 due to blocking of its receptors.
Mechanism of ActionBrodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.
ToxicityNA
MetabolismNA
AbsorptionNA
4.62 L.
Clearance0.223 L/day.
CategoriesAntineoplastic and Immunomodulating Agents
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionThe risk or severity of adverse effects can be increased with combination of drugs like BCG, Denosumab, Fingolimod, G17DT, GI-5005, INGN 201, INGN 225, Leflunomide, Natalizumab, Pimecrolimus.
TargetInterleukin 17 receptor A
Brand NameSiliq
CompanyNA
Brand DescriptionNA
Prescribed ForSILIQâ„¢ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
Chemical NameNA
FormulationEach SILIQ single-dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8.
Physical Appearance sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution
Route of AdministrationSubcutaneous
Recommended DosageThe recommended SILIQ dose is 210 mg administered by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
ContraindicationSILIQ is contraindicated in patients with Crohn’s disease because SILIQ may cause worsening of disease
Side EffectsSuicidal Ideation and Behavior, Infection and Crohn’s Disease
Useful Link 1Link
Useful Link 2NA
RemarksNA